Consumer advocacy organization pushes back on Health Canada’s proposal to restrict vape flavours

Events
May.31.2022
“Flavour restrictions either work or they do not when it comes to preventing youth use. You cannot say they’re needed for nicotine vaping but not alcohol and cannabis.”

The poll was conducted online by Delphi Polling & Consulting between Apr. 29 and May 10, through a demographically representative sample of 1,200 Canadians of legal vaping age in their respective province. The survey was available in English and French and used interlocking quotas with targets set out in the most recent Census around age, gender, province and language (for Quebec).

 

The organization adds that banning most flavoured vaping products could push some consumers back to smoking, ultimately creating worse health outcomes. They also argue that if flavour restrictions are placed on nicotine products, similar restrictions should be placed on cannabis and alcohol products.

 

“Flavour restrictions either work or they do not when it comes to preventing youth use. You cannot say they’re needed for nicotine vaping, but not alcohol and cannabis. As an organization that defends consumer choice, we are opposed to prohibitions generally and would like to see more sophisticated policy-making from Health Canada,” Cran said.

 

The proposed amendments to the Tobacco and Vaping Products Act (Flavours)would restrict the promotion of flavours to tobacco or mint/menthol. The use of all sugars and sweeteners as well as flavouring ingredients, with limited exceptions, would also be prohibited in the manufacture of vaping products.

 

Health Canada notes that Canadians had the opportunity to provide commentson the regulatory proposal during the Canada Gazette, Part I, public comment period, which started on June 19, 2021 and lasted 75 days.

 

source:The GrowthOp

The organization argues that banning most flavoured vaping products could push some consumers back to smoking, ultimately creating worse health outcomes. /

 

Bonnie Herzog:U.S. nicotine market seen at about $67B in revenue by 2035 as smoke-free expands
Bonnie Herzog:U.S. nicotine market seen at about $67B in revenue by 2035 as smoke-free expands
Goldman Sachs Managing Director Bonnie Herzog said the U.S. nicotine market is attractive and growing, with total revenue projected to reach about $67 billion by 2035. She expects cigarettes to account for a smaller share of revenue (47%) as smoke-free revenue expands and becomes a key driver of industry profit growth. Herzog said smoke-free products represent about 48% of U.S. nicotine volumes today and could rise to roughly 75% by 2035.
Mar.04 by 2FIRSTS.ai
Virginia Restricts Vape Sales to Products Listed in State Directory From April 1
Virginia Restricts Vape Sales to Products Listed in State Directory From April 1
From April 1, vape shops in Virginia may sell only liquid nicotine and vapor products listed in the state directory. The Office of the Attorney General has recommended that commonwealth attorneys begin enforcing the 2024 law.
Apr.02 by 2FIRSTS.ai
UKVIA Says VApril 2026 Will Highlight Consumer Impact of Tobacco and Vapes Bill
UKVIA Says VApril 2026 Will Highlight Consumer Impact of Tobacco and Vapes Bill
The UK Vaping Industry Association said it will launch the ninth annual VApril campaign next month. The association described VApril as the world’s largest vape awareness initiative and said it has for almost a decade supported adult smokers looking to quit through vaping by providing evidence-based information, expert insights and practical guidance
Mar.24 by 2FIRSTS.ai
Indonesian drug agency chief proposes ban on e-cigarettes and e-liquid containing harmful substances
Indonesian drug agency chief proposes ban on e-cigarettes and e-liquid containing harmful substances
Indonesian drug agency chief proposes ban on e-cigarette and e-liquid in new draft law, citing dangerous substances found.
Apr.08 by 2FIRSTS.ai
Qnovia’s Heat-Free Inhalable Nicotine Replacement Therapy Posts Positive First-in-Human Data, Advances FDA and MHRA Filings as Funding Expands
Qnovia’s Heat-Free Inhalable Nicotine Replacement Therapy Posts Positive First-in-Human Data, Advances FDA and MHRA Filings as Funding Expands
U.S.-based medical startup Qnovia Inc. reported positive results from its first-in-human clinical trial of RespiRx, an inhalable nicotine replacement therapy (NRT) device designed to support smoking cessation.
Innovation
Feb.24
Study Says Europe’s Illicit Disposable Vape Market to Reach EUR 6.6 Billion in 2026
Study Says Europe’s Illicit Disposable Vape Market to Reach EUR 6.6 Billion in 2026
A new study by the Fraunhofer Institute says the rapidly expanding illicit market for disposable e-cigarettes is undermining European regulation, fuelling youth vaping and causing significant tax losses. The study says the illicit market is worth EUR 6.6 billion in 2026 and is projected to rise to EUR 10.8 billion by 2030. It adds that a significant share of the disposable vape market now operates outside the regulatory framework established by the EU Tobacco Products Directive.
Mar.13 by 2FIRSTS.ai